-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Q+r9exl3hW4tb9e/kBpAFuog5O+Jv7RqZvVaQt8+OUYo46dVlWaBUNlmV6Ddu+YQ GxnfzcWIj5fWtLVBPbHvxw== 0000899140-08-001670.txt : 20080905 0000899140-08-001670.hdr.sgml : 20080905 20080905154035 ACCESSION NUMBER: 0000899140-08-001670 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20080905 DATE AS OF CHANGE: 20080905 GROUP MEMBERS: IVAX CORPORATION SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: IVAX DIAGNOSTICS INC CENTRAL INDEX KEY: 0001095858 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 113500746 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-58691 FILM NUMBER: 081058662 BUSINESS ADDRESS: STREET 1: 2140 NORTH MIAMI AVENUE CITY: MIAMI STATE: FL ZIP: 90802 BUSINESS PHONE: 5624917180 MAIL ADDRESS: STREET 1: 2140 NORTH MIAMI AVENUE CITY: MIAMI STATE: FL ZIP: 33127 FORMER COMPANY: FORMER CONFORMED NAME: B2BSTORES COM INC DATE OF NAME CHANGE: 19990928 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: TEVA PHARMACEUTICAL INDUSTRIES LTD CENTRAL INDEX KEY: 0000818686 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 5 BAZEL ST STREET 2: P O B 3190 CITY: PETACH TIKVA STATE: L3 ZIP: 49131 MAIL ADDRESS: STREET 1: TEVA PHARMACEUTICAL INDUSTRIES LIMITED STREET 2: 5 BAZEL ST PO B 3190 CITY: PETACH TIKVA STATE: L3 ZIP: 49131 SC 13D/A 1 i090508.txt SECOND AMENDMENT - - SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 2) Under the Securities Exchange Act of 1934* IVAX DIAGNOSTICS, INC. - -------------------------------------------------------------------------------- (Name of Issuer) Common Stock, par value $0.01 per share - -------------------------------------------------------------------------------- (Title of Class of Securities) 45070W 10 9 - -------------------------------------------------------------------------------- (CUSIP Number) IVAX Corporation c/o Richard S. Egosi, Esq. Teva Pharmaceuticals USA, Inc. 425 Privet Road P.O. Box 1005 Horsham, PA 19044-8005 (215) 293-6400 - -------------------------------------------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) Copies to: Peter H. Jakes, Esq. Jeffrey S. Hochman, Esq. Willkie Farr & Gallagher LLP 787 Seventh Avenue New York, NY 10019-6099 (212) 728-8000 September 2, 2008 - -------------------------------------------------------------------------------- (Date of Event which Requires Filing of this Schedule) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.ss. 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box: [ ] NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 240.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). SCHEDULE 13D/A - ----------------------------- --------------------- CUSIP No. 45070W 10 9 Page 2 of 5 Pages - ----------------------------- --------------------- - ----------- -------------------------------------------------------------------- 1 NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Teva Pharmaceutical Industries Limited - ----------- -------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ] - ----------- -------------------------------------------------------------------- 3 SEC USE ONLY - ----------- -------------------------------------------------------------------- 4 SOURCE OF FUNDS* Not applicable - ----------- -------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) [ ] - ----------- -------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION Israel - --------------------- --------- ------------------------------------------------ 7 SOLE VOTING POWER 0 --------- ------------------------------------------------ 8 SHARED VOTING POWER NUMBER OF SHARES BENEFICIALLY OWNED 0 BY EACH REPORTING --------- ------------------------------------------------ PERSON WITH 9 SOLE DISPOSITIVE POWER 0 --------- ------------------------------------------------ 10 SHARED DISPOSITIVE POWER 0 - ----------- -------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON 0 - ----------- -------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [ ] - ----------- -------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0.0% - ----------- -------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON* CO - ----------- -------------------------------------------------------------------- SCHEDULE 13D/A - ----------------------------- --------------------- CUSIP No. 45070W 10 9 Page 3 of 5 Pages - ----------------------------- --------------------- - ----------- -------------------------------------------------------------------- 1 NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) IVAX Corporation - ----------- -------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ] - ----------- -------------------------------------------------------------------- 3 SEC USE ONLY - ----------- -------------------------------------------------------------------- 4 SOURCE OF FUNDS* Not applicable - ----------- -------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) [ ] - ----------- -------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION State of Florida - --------------------- --------- ------------------------------------------------ 7 SOLE VOTING POWER 0 --------- ------------------------------------------------ 8 SHARED VOTING POWER NUMBER OF SHARES BENEFICIALLY OWNED 0 BY EACH REPORTING --------- ------------------------------------------------ PERSON WITH 9 SOLE DISPOSITIVE POWER 0 --------- ------------------------------------------------ 10 SHARED DISPOSITIVE POWER 0 - ----------- -------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON 0 - ----------- -------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [ ] - ----------- -------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0.0% - ----------- -------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON* CO - ----------- -------------------------------------------------------------------- This Amendment No. 2 ("Amendment No. 2") amends the Schedule 13D filed with the Securities and Exchange Commission (the "SEC") on March 26, 2001 by IVAX Corporation ("IVAX"), a Florida corporation and wholly-owned subsidiary of Teva (as defined below), as amended by Amendment No. 1 to Schedule 13D/A filed with the SEC on January 26, 2006 (as amended through this Amendment No. 2, the "Schedule 13D"), and is being filed on behalf of IVAX and Teva Pharmaceutical Industries Limited, an Israeli corporation ("Teva" and, together with IVAX, the "Filers"). The Schedule 13D relates to the common stock, par value $0.01 per share (the "Common Stock"), of IVAX Diagnostics, Inc., a Delaware corporation (the "Company"). Item 5. Interest in Securities of the Issuer. Item 5 is amended by adding the following: Pursuant to stock purchase agreements entered into by IVAX and each of Debregeas & Associes Pharma SAS, a French Company ("Debregeas"), UMBRIA LLC, a company organized under the laws of the Republic of the Seychelles ("Umbria"), and Paul F. Kennedy (together with Debregeas and Umbria, the "Buyers"), the Buyers purchased from IVAX all of the 20 million shares of Common Stock that IVAX owned for an aggregate purchase price of $14 million. As of the date hereof, neither of the Filers own any Common Stock. SIGNATURES After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct. Dated: September 5, 2008 TEVA PHARMACEUTICAL INDUSTRIES LIMITED By: /s/ Doron Blachar ---------------------------------------- Name: Doron Blachar Title: Vice President Finance By: /s/ Dov Bergwerk ---------------------------------------- Name: Dov Bergwerk Title Legal IVAX CORPORATION By: /s/ Deborah Griffin ---------------------------------------- Name: Deborah Griffin Title: Vice President and Treasurer By: /s/ Austin D. Kim ---------------------------------------- Name: Austin D. Kim Title Assistant Secretary [SIGNATURE PAGE TO AMENDMENT NO. 2 TO SCHEDULE 13D WITH RESPECT TO IVAX DIAGNOSTICS, INC.] -----END PRIVACY-ENHANCED MESSAGE-----